Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
Terminated
FPC De Kijvelanden, Poortugaal
Phase 4
2006-11-01
In a double blind randomized clinical trial with cross-over design, treatment using
naratriptan will be compared to placebo within a group of 30 convicts with psychiatric
disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to
conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that
addition of naratriptan to the individual treatment regime reduces aggression -and improves
general outcome- as compared to addition of placebo and is well tolerated in this group and
under these conditions.
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
Terminated
UMC Utrecht
Phase 4
2006-11-01
In a double blind randomized clinical trial with cross-over design, treatment using
naratriptan will be compared to placebo within a group of 30 convicts with psychiatric
disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to
conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that
addition of naratriptan to the individual treatment regime reduces aggression -and improves
general outcome- as compared to addition of placebo and is well tolerated in this group and
under these conditions.
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
Terminated
Clinvest
Phase 4
2006-10-01
The purpose of this study is to determine whether naratriptan, a medication approved for
treatment of migraine, is effective in the treatment of post traumatic headache associated
with cognitive dysfunction.
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
Terminated
GlaxoSmithKline
Phase 4
2006-10-01
The purpose of this study is to determine whether naratriptan, a medication approved for
treatment of migraine, is effective in the treatment of post traumatic headache associated
with cognitive dysfunction.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
